Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 18/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | BPTF | Q12830 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492787 | 0.88 | GRM2 (0.61) | GRM2 | |
| SCHEMBL30423755 | 0.88 | GRM2 (0.61) | GRM2 | |
| SCHEMBL22622584 | 0.86 | GRM2 (0.55) | GRM2 | |
| SCHEMBL22622668 | 0.83 | GRM2 (0.47) | GRM2 | |
| SCHEMBL22950229 | 0.80 | GRM2 (0.69) | GRM2 | |
| SCHEMBL22950230 | 0.78 | GRM2 (0.43) | GRM2 | |
| SCHEMBL25859202 | 0.78 | GRM2 (0.53) | GRM2 | |
| SCHEMBL22622566 | 0.77 | GRM2 (0.82) | GRM2 | |
| SCHEMBL22622565 | 0.77 | GRM2 (0.82) | GRM2 | |
| SCHEMBL22950261 | 0.76 | GRM2 (0.82) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210850-A1 | PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-10953008-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20210030754-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210850-A1 | PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES | CYP3A5, CYP2F1, CYP4Z1 | GRM2 3682/4885LCK 2937/4885KIT 324/4885 |
| US-10953008-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor | GRM5, GRM1, GRM2 | GRM2 3/4885LCK 1643/4885KIT 4191/4885 |
| US-20210030754-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | GRM5, GRM6, GRM2 | GRM2 3/4885LCK 1410/4885KIT 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.